Brind.

Kymera Therapeutics was listed on NASDAQ and disclosed insider stock sales via SEC filings.

3 reports, 1 independent Updated Jun 30

Gone quiet

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Kymera Therapeutics was listed on NASDAQ and disclosed insider stock sales via SEC filings.

Who's involved

What this event is mainly about

Kymera Therapeutics Nasdaq SEC

Keep exploring

The entities involved

Kymera Therapeutics
biopharmaceutical company

Nothing else this week.
Nasdaq
American fully electronic stock exchange
- BHAV Acquisition Corp II units are set to trade on Nasdaq following SEC approval of the registration statement, with Maxim Group as the book-running manager.04:02
- Stanley Druckenmiller invested $6 billion around the Nasdaq peak on October 28, 2026.01:40
SEC
Slovak company
- Starton filed its S-1 registration statement and plans to list on the Nasdaq exchange.00:14
- James Currier serves as CEO of the company, which reports to the SEC.Wed 20:46

Related events

KYTX was listed on the Nasdaq stock exchange on October 22, 2026.Thu 20:16

Coverage

Newest first; wire copies grouped